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Von Recklinghausen neurofibromatosis (neurofibromatosis type
1, NF1, McKusick no. 162200) is one of the most common
human genetic disorders, with an incidence of approximately 1
in 3500 in all ethnic groups (1). The mutation rate is close to
1 in 104 meioses, and about half the cases result from new
mutations (2). The clinical hallmarks of the disease are cutaneous
or subcutaneous neurofibromas and hyperpigmented cafe"-au-lait
skin patches, but the disorder presents a remarkable phenotypic
variability, with many other clinical signs such as axillary
freckling, Lisch nodules, bone deformities, or learning
disabilities. In addition, NF1 patients show an increased
frequency of nervous system tumors, such as malignant
neurofibrosarcomas, optic nerve gliomas, and pheochromo-
cytomas. The NF1 locus was mapped by linkage analysis to
chromosome 17qll.2 (3-5), and subsequently the NF1 gene
was identified by positional cloning (6-8). The gene, which
consists of 51 exons extending over a genomic distance of
approximately 350 kilobases, produces a ubiquitously-expressed
mRNA of 13 kilobases (kb) (6-8). The gene codes for the protein
neurofibromin, which contains a domain related to GAP
(GTPase-activating protein) (9), and is capable of down-regulating
ras by stimulating its intrinsic GTPase activity (10, 11). Many
germline mutations have been identified in patients with NF1 (see
ref. 12 for review). The observation of loss of heterozygosity
in at least one patient (13) supports a tumor suppressor gene
hypothesis for NF1.
In screening for mutations in 42 NF1 patients by RT-PCR,
we used a set of 7 primer pairs to amplify the coding region of
the NF1 cDNA. We found a 59 year-old Swiss patient (C34-1)
with NF1 where RT-PCR revealed one abnormally small
amplification product, of about 1 kb instead of the expected 1.3
kb (Figure 1). The amplification product extends from the 3' end
of exon 28 to the 5' end of exon 34. Although no formal
quantification was performed, a consistent difference in the
intensity of the two bands suggested that slightly less mutant than
normal mRNA was present.
Sequence analysis revealed that the abnormal cDNA lacked
the 280 nucleotides of exon 33 and had a perfect juxtaposition
of exons 32 and 34. Genomic DNA sequences from nucleotide
47773 (exon 32) to nucleotide 49075 (TVS 34) were determined
from uncloned PCR products (see Figure 2). A single nucleotide
change was found, an A—G transition at nucleotide +4 of the
IVS33 splice donor site (GTG/gtaagt to GTG/gtaggt; Figure 2).
The relative frequencies of the four nucleotides at the +4 position
of mammalian splice donor sites are: A — 0.71; G — 0.12; C
- 0.08; T - 0.09 (14).
Although G occurs at position +4 in 12% of splice donor sites,
we hypothesized that, in the context of this intron, the IVS33
+ 4 A - G transition was responsible for the splicing error and
was disease-causing. In order to exclude the possibility that this
alteration was merely a polymorphism, we used a mismatch PCR
assay to detect the A—G transition. By introducing a single
mismatch in the sequence of one primer, the presence of G
(mutant) rather than A (normal) at the mutation site creates a
Sau96l restriction site in the amplification product, easily detected
by subsequent digestion (Figure 3). The +4 A—G transition was
not present in 170 non-NFl chromosomes from unrelated Swiss
individuals (data not shown), excluding the possibility of it being
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Figure 1. RT-PCR of NF1 cDNA exons 28 to 34. A. The specific primers for
this PCR were 5151L (5'-GGTATTCCACAATGCTCTCAAG-3') and 6457R
(5'-CTGACTTGACTTTGCTAATGCC-3'), numbered according to EMBL
database, accession no. M89914. B. The lower band of 1.0 kb corresponds to
the abnormal RT-PCR product which lacks exon 33.
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Figure 2. Structure of the genomic region surrounding the IVS33 splice donor site. The mutation is shown at the bottom. The heavy lines above represent the areas
for which the'genomic sequence was determined. Nucleotide numbers are according to the EMBL database, accession nos L05367 and LO3723,
a common polymorphism. In addition, the aberrant splicing of
exon 33 is predicted to result in a change of the reading frame
and a loss of 777 of the 2811 amino acids of the mature protein.
Finally, the mutation correlated with the disease in the patient's
family: the mildly-affected son but not the asymptomatic daughter
(28 year-old dizygotic twins), had inherited the mutation (Figure
3). We are thus led to conclude that mutations at nucleotide +4
of the splice donor site may lead to abnormal splicing and human
disease.
The mutation reported here is the second independent case of
NF1 with skipping of exon 33, the first being due to the insertion
of an Alu retrotransposon in the 3' end of IVS32 (15). The 31
year-old patient of ref. 15 had no cafe'-au-lait spots but one
cutaneous neurofibroma, axillary freckling, Lisch nodules,
cervical root tumors and macrocephaly. Our patient (C34-1) had
typical but relatively mild dermatological features (multiple small
neurofibromas, and three cafe'-au-lait spots), and from the age
of 48 showed progressive sensorimotor impairment due to
multiple radicular neurofibromas, mostly in the intervertebral
foramen. His affected son, who has five cafe'-au-lait spots and
three neurofibromas, had a history of excision of minor cysts
in his childhood.
Three other +4 mutations at splice donor sites have been
reported in human disorders. The first (A —G) was detected by
genomic sequencing in the IVS19 of the CFTR gene in a patient
with CF (16); however, the possibility of exon skipping was not
investigated. The second +4 mutation (also A —G) was in the
IVS33 of the COL1A2 gene, and led to the use of an alternative
splice site within the intron in a patient with a non-lethal form
of osteogenesis imperfecta (17). Finally, an IVS4 +4 A —T
transversion has been reported in the FACC gene in Ashkenazi
Jewish patients with Fanconi anemia, where the mutation
apparently results in either complete or partial excision of exon
4 during splicing (18).
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fragments from normal and mutant DNAs after Sou96I digestion. B. The proband
and his son are heterozygous for the +4 A—G mutation as shown by the presence
of the 91 bp fragment.
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